文献速递生殖医学妇科

抗苗勒管激素作为癌症儿童及女性卵巢储备和早发性卵巢功能不全标志物的系统综述

Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
PubMed 文献 · Hum Reprod Update · 2022-01-01

该系统综述纳入92篇文献共9183例患者,评估抗苗勒管激素(AMH)作为癌症治疗前后卵巢储备和早发性卵巢功能不全(POI)生物标志物的价值。化疗或放疗后69/75项研究(92%)报告AMH降低或检测不到,降幅42%至低于检测下限,多数报告平均或中位下降≥90%;纵向研究中33/42项(79%)报告至少部分恢复。AMH可用于识别癌症治疗对卵巢功能的损伤,但将其与生育力、生殖寿命或POI时间关联的数据非常有限。

要点

  • 癌症治疗后AMH降低或检测不到见于69/75项研究(92%),降幅42%至低于检测下限。
  • 纵向研究中33/42项(79%)报告随访时AMH至少部分恢复,但效应量变异很大。
  • 16/31项(52%)研究中月经稀发或闭经与治疗后较低AMH相关,与即将发生的POI一致。

核心结论

  • AMH可用于识别癌症治疗对卵巢功能的损伤,适用于个体女性包括青春期前和青春期女孩,也可用于比较不同治疗方案、年龄和治疗前AMH水平的人群。
  • 虽有证据支持AMH用于癌症治疗后POI的诊断,但需要在不同诊断/治疗方案和患者年龄中进一步研究以明确其价值并量化其预测价值。
  • AMH临床使用的主要局限是治疗后AMH水平与生育力、生殖寿命时长或POI时间之间关联的数据非常有限,进一步研究应分析这些临床相关结局。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Cochrane对照试验中心注册库截至2021年4月1日的文献。
  • 采用非随机干预研究偏倚风险(ROBINS-I)方案进行偏倚评价并结合质量定性评估。
  • 基于年龄、癌症类型和随访时长建立探索性亚组。
  • 经质量和偏倚评价后纳入92篇文献,共9183例患者。

主要发现

  • 化疗或放疗后69/75项研究(92%)一致发现AMH降低或检测不到,降幅范围为42%至低于检测下限的浓度,许多研究报告平均或中位下降≥90%。
  • 纵向数据分析(42项研究)中,33/42项(79%)报告随访时AMH至少部分恢复,但效应估计变异很大,反映AMH水平受抗癌治疗(即所用化疗方案和所需治疗周期数)强烈影响,恢复及其程度由治疗方案、年龄和治疗前AMH水平决定。
  • 16/31项(52%)文献中月经稀发或闭经与治疗后较低AMH相关,与即将发生的POI一致,尽管低或检测不到AMH的患者也有月经和/或妊娠报告。
  • 癌症治疗后儿科患者的长期(>5年)随访中,14/20项研究(70%)发现AMH显著低于对照组,效应量从AMH完全丧失到完全恢复变异很大,取决于治疗暴露,与成年患者一样。

临床怎么用

  • AMH可用于识别癌症治疗对卵巢功能的损伤,可应用于个体女性包括青春期前和青春期女孩,也可用于比较不同治疗方案、年龄和治疗前AMH水平的人群。
  • 虽有证据支持AMH用于癌症治疗后POI的诊断,但需在不同诊断/治疗方案和患者年龄中进一步研究以明确并量化其预测价值。
  • AMH临床使用的主要局限是治疗后AMH水平与生育力、生殖寿命时长或POI时间之间关联的数据非常有限。

局限性

  • 效应估计高度可变,反映AMH水平受抗癌治疗(即所用化疗方案和所需治疗周期数)强烈影响。
  • 效应量变异很大,从AMH完全丧失到完全恢复,取决于治疗暴露。
  • AMH临床使用的主要局限是治疗后AMH水平与生育力、生殖寿命时长或POI时间之间关联的数据非常有限。
  • 需要在不同诊断/治疗方案和患者年龄中进一步研究以明确AMH对POI诊断的价值并量化其预测价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Female patients undergoing anticancer treatment are at elevated risk of adverse ovarian outcomes including infertility and premature ovarian insufficiency (POI), which is associated with short- and long-term health risks. Anti-Müllerian hormone (AMH) is a key biomarker of ovarian reserve, but its role prior to and after cancer treatment is less well understood. OBJECTIVE AND RATIONALE: To conduct a systematic review evaluating AMH as a biomarker of ovarian reserve and POI before and after anticancer treatment, which has become a pressing clinical issue in reproductive medicine. There are a large number of observational studies, but differences in patient groups, cancer diagnoses and study design make this a confusing field that will benefit from a thorough and robust review. SEARCH METHODS: A systematic literature search for AMH in women with cancer was conducted in PubMed, Embase and Cochrane Central Register of Controlled Trials up to 1 April 2021. Bias review was conducted using the Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) protocol along with qualitative assessment of quality. Exploratory subgroups were established based on age, cancer type and length of follow-up. OUTCOMES: Ninety-two publications (N = 9183 patients) were included in this analysis after quality and bias review. Reduced/undetectable AMH was consistently identified in 69/75 studies (92%) following chemotherapy or radiotherapy, with reductions ranging from 42% to concentrations below the limit of detection, and many reporting mean or median declines of ≥90%. Where longitudinal data were analysed (42 studies), a majority (33/42 (79%)) of studies reported at least partial recovery of AMH at follow-up, however, effect estimates were highly variable, reflecting that AMH levels were strongly impacted by anticancer treatment (i.e. the chemotherapy regimen used and the number of treatment cycles need), with recovery and its degree determined by treatment regimen, age and pre-treatment AMH level. In 16/31 (52%) publications, oligo/amenorrhoea was associated with lower post-treatment AMH consistent with impending POI, although menstruation and/or pregnancy were reported in patients with low or undetectable AMH. Long-term (>5 years) follow-up of paediatric patients following cancer treatment also found significantly lower AMH compared with control groups in 14/20 (70%) of studies, with very variable effect sizes from complete loss of AMH to full recovery depending on treatment exposure, as in adult patients. WIDER IMPLICATIONS: AMH can be used to identify the damaging effect of cancer treatments on ovarian function. This can be applied to individual women, including pre-pubertal and adolescent girls, as well as comparing different treatment regimens, ages and pre-treatment AMH levels in populations of women. While there was evidence for its value in the diagnosis of POI after cancer treatment, further studies across a range of diagnoses/treatment regimens and patient ages are required to clarify this, and to quantify its predictive value. A major limitation for the use of AMH clinically is the very limited data relating post-treatment AMH levels to fertility, duration of reproductive lifespan or time to POI; analysis of these clinically relevant outcomes will be important in further research.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Anderson RA, Cameron D, Clatot F, et al. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update. 2022. PMID: 35199161. doi:10.1093/humupd/dmac004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。